Chronic Myeloid Leukemia Face-Off: Memorial Sloan Kettering vs Dana-Farber - Episode 2

The OPTIC Trial: A Ponatinib Dose-Ranging Study in Chronic Myeloid Leukemia

Michael Mauro, MD, presents data on a phase 2 ponatinib dose-ranging study in chronic-phase CML.